Radioactive particles aim to fight ovarian cancer spread

NCT ID NCT03732768

Completed Disease control Sponsor: Oncoinvent Solutions AS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new treatment called Radspherin for women with ovarian cancer that has returned and spread in the abdomen. Radspherin consists of tiny radioactive particles injected directly into the belly after surgery to remove visible tumors. The study involved 21 participants and aimed to find a safe dose and check for side effects. It is a first step to see if this approach could help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radspherin (radioactive particles injected into the abdomen)
What this could lead to: If it works, this could point toward a new treatment option for ovarian cancer that has spread in the abdomen.
What could go wrong: This is a very early phase 1 trial with only 21 participants, so it is too soon to know if it is effective or safe for wider use. The therapy uses radiation, which may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian cancer ovarian carcinoma peritoneal carcinomatosis peritoneal neoplasm primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER PERITONEAL CARCINOMATOSIS

Contacts and locations

Locations

Clínica Universidad de Navarra

Madrid, Spain
Clínica Universidad de Navarra

Pamplona, Spain
The Norwegian Radiumhospital

Oslo, Norway
UZ Leuven

Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.